Value
2.9/10data confidence 67%| Component | Sub-score |
|---|---|
| P/E | 4.7 |
| P/S | 3.7 |
| EV/EBITDA | 0.0 |
| Analyst target | 3.0 |
- ▸Expensive valuation
SLNO · Why this verdict
Why Soleno Therapeutics (SLNO) is rated SELL
Updated
Model-generated analysis — not investment advice. Not a registered investment advisor. Past performance does not guarantee future results.
Show full disclosure ▾Hide full disclosure ▴
About TrendMatrix. TrendMatrix is a publisher of general securities research and market commentary. We publish on a regular schedule. All content is the same for every subscriber in a tier — we do not provide personalized investment advice and we do not take into account any individual subscriber's financial situation, investment objectives, risk tolerance, tax situation, or holdings.
Not investment advice. TrendMatrix is not a registered investment adviser. Our content is for informational and educational purposes only. Consult your own licensed investment adviser, broker, or tax professional before making any investment decision.
Conflicts and positions. The TrendMatrix editorial team frequently holds personal long-term positions in securities discussed. We disclose positions held at the time of publication on each piece. We maintain a trading-window policy: we do not initiate or close positions in the same direction as a TrendMatrix publication within 24 hours before or 72 hours after publication.
No paid promotion. TrendMatrix does not accept payment from any issuer, broker, or third party in exchange for coverage of any security. Our sole compensation is subscription revenue.
No fiduciary duty. No fiduciary, advisory, or agency relationship is created between you and TrendMatrix by reading our content or subscribing to our service.
Performance. Past performance is not indicative of future results. Performance figures reflect the published model only and do not reflect any individual subscriber's actual results.
VerdictSELL
Overall score5.3/10
ConfidenceMEDIUM
MacroNEUTRAL
Thesis pillars
| Pillar | Expectation | Trend |
|---|---|---|
Following the commercial launch of VYKAT XR for Prader-Willi syndrome, Soleno has achieved a perfect 9 out of 9 Piotroski F-Score with a 26% return on equity and 34% net margins, placing it among the strongest quality profiles in the biotechnology sector. Quality breakdown | Net margins remain above 25% and Piotroski F-Score stays at 7 or higher over the next 12 months, confirming the commercial launch created durable profitability. | →Stable |
| CounterSingle-product biotechnology profitability can collapse rapidly if the commercial launch encounters reimbursement barriers, label restrictions, or competitive entrants; VYKAT XR operates in a rare disease niche with limited commercial precedent. | ||
RSI has reached 93, a deeply overbought reading indicating recent buying has been extreme, and the stock is trading above its take-profit level based on analyst targets, leaving essentially no upside margin against technical resistance. Momentum breakdown | RSI pulls back below 70 within 3 months as some of the overbought condition unwinds, providing a better risk-adjusted entry for new buyers. | →Stable |
| CounterStocks with strong fundamental momentum — such as a commercially successful rare disease drug launch — can sustain elevated RSI readings for extended periods; the overbought condition may persist longer than traditional technical analysis would predict. | ||
Essentially all revenue and earnings power is concentrated in a single product, VYKAT XR, meaning any adverse development including reimbursement denials, safety signals, or manufacturing disruptions could eliminate the entire earnings stream overnight. Bear case | VYKAT XR maintains formulary coverage with at least 3 major pharmacy benefit managers and net revenue grows by more than 20% year-over-year within 12 months. | →Stable |
| CounterRare disease drugs targeting small orphan populations face limited competition by design; the FDA's orphan drug designation and the niche patient population make generic and competitive entry structurally difficult. | ||
Short interest of 18% combined with a quality score of 8.8 creates a short squeeze setup: if positive commercial data reinforces the fundamental case, short sellers covering could amplify price appreciation significantly beyond what fundamentals alone would justify. Risk breakdown | Short interest falls below 10% within 9 months as short sellers recognize the commercial traction and reduce bearish positions. | →Stable |
| CounterHigh short interest in a specialty pharmaceutical company often reflects sophisticated institutional skepticism about the drug's commercial durability, reimbursement risk, or the breadth of the treatable patient population. | ||
Following the commercial launch of VYKAT XR for Prader-Willi syndrome, Soleno has achieved a perfect 9 out of 9 Piotroski F-Score with a 26% return on equity and 34% net margins, placing it among the strongest quality profiles in the biotechnology sector.
→StableQuality breakdown
- Expectation
- Net margins remain above 25% and Piotroski F-Score stays at 7 or higher over the next 12 months, confirming the commercial launch created durable profitability.
CounterSingle-product biotechnology profitability can collapse rapidly if the commercial launch encounters reimbursement barriers, label restrictions, or competitive entrants; VYKAT XR operates in a rare disease niche with limited commercial precedent.
RSI has reached 93, a deeply overbought reading indicating recent buying has been extreme, and the stock is trading above its take-profit level based on analyst targets, leaving essentially no upside margin against technical resistance.
→StableMomentum breakdown
- Expectation
- RSI pulls back below 70 within 3 months as some of the overbought condition unwinds, providing a better risk-adjusted entry for new buyers.
CounterStocks with strong fundamental momentum — such as a commercially successful rare disease drug launch — can sustain elevated RSI readings for extended periods; the overbought condition may persist longer than traditional technical analysis would predict.
Essentially all revenue and earnings power is concentrated in a single product, VYKAT XR, meaning any adverse development including reimbursement denials, safety signals, or manufacturing disruptions could eliminate the entire earnings stream overnight.
→StableBear case
- Expectation
- VYKAT XR maintains formulary coverage with at least 3 major pharmacy benefit managers and net revenue grows by more than 20% year-over-year within 12 months.
CounterRare disease drugs targeting small orphan populations face limited competition by design; the FDA's orphan drug designation and the niche patient population make generic and competitive entry structurally difficult.
Short interest of 18% combined with a quality score of 8.8 creates a short squeeze setup: if positive commercial data reinforces the fundamental case, short sellers covering could amplify price appreciation significantly beyond what fundamentals alone would justify.
→StableRisk breakdown
- Expectation
- Short interest falls below 10% within 9 months as short sellers recognize the commercial traction and reduce bearish positions.
CounterHigh short interest in a specialty pharmaceutical company often reflects sophisticated institutional skepticism about the drug's commercial durability, reimbursement risk, or the breadth of the treatable patient population.
TrendMatrix Research · core thesis
Engine thesis — one sentence
Soleno Therapeutics has achieved a 9 out of 9 Piotroski F-Score with 34% net margins and a 26% return on equity following the commercial launch of VYKAT XR, but the stock is overbought at an RSI of 93 and is trading above analyst targets, creating high downside risk to valuation.
Falsifiable statement — pillar-level invalidators below. Engine-derived; not personalized advice.
Per-dimension breakdown
Quality
8.8/10data confidence 100%| Component | Sub-score |
|---|---|
| ROE | 8.8 |
| ROA | 8.0 |
| Gross margin | 10.0 |
| Op margin | 10.0 |
| Net margin | 10.0 |
| Current ratio | 7.4 |
| FCF quality | 6.8 |
| Moat | 8.0 |
| Piotroski F | 10.0 |
- ▸Excellent ROE: 26%
- ▸Strong margins: 34%
- ▸Wide economic moat
- ▸Compounder quality: strong returns + growth
Growth
5.0/10data confidence 50%Momentum
6.0/10data confidence 100%| Component | Sub-score |
|---|---|
| RSI | 3.3 |
| MACD | 0.0 |
| OBV | 10.0 |
| MA position | 7.5 |
| Volume | 10.0 |
| vol acceleration | 5.5 |
- ▸Overbought (RSI 93)
- ▸Volume accumulation (rising OBV)
- ▸Above 200-MA but MA slope flat/negative + RSI 93 (late-cycle distribution risk)
Sentiment
5.0/10data confidence 67%| Component | Sub-score |
|---|---|
| Analyst rating | 5.0 |
| Price target | 5.0 |
Insider
5.0/10data confidence 50%Peer rank
4.5/10data confidence 80%| Component | Sub-score |
|---|---|
| value rank | 4.7 |
| quality rank | 8.4 |
| growth rank | 5.0 |
- ▸Superior ROE vs peers
Technical
1.0/10data confidence 100%| Component | Sub-score |
|---|---|
| bollinger | 1.4 |
| support resistance | 0.0 |
| 52w position | 1.7 |
Risk (lower is worse)
6.9/10data confidence 100%| Component | Sub-score |
|---|---|
| short interest | 7.9 |
| days to cover | 10.0 |
| volatility | 10.0 |
| put call | 0.0 |
| implied vol | 4.1 |
| debt equity | 9.6 |
- ▸Short squeeze setup: 18% short, quality 7.5
- ▸Elevated put/call: 4.00
- ▸Concentration risks: 1 HIGH (10-K Item 1A — sized via position_sizing, validated via buy_confidence)
Catalyst
7.2/10data confidence 75%| Component | Sub-score |
|---|---|
| earnings history | 6.7 |
| earnings timing | 5.0 |
| surprise avg | 10.0 |
- ▸Strong earnings: 3B/1M
How the verdict was assembled
Engine trigger
Multiple concerning factors. Consider reducing position.
Engine technical detail
verdict_path:
L4:PATH_F_SELLPassed (7)
- MOMENTUM:6.0>=5.5
- INSIDER:OK
- DEATH_CROSS:QUALITY_MOMENTUM_EXEMPT
- NEWS_EVENTS:NONE_RECENT
- EARNINGS_PROXIMITY:33d clear
- SEMI_CYCLE_PEAK:CLEAR
- MATERIALS_CYCLE_PEAK:CLEAR
Failed (1)
- ASYMMETRY:-0.9=NEGATIVE
Warning (2)
- DEATH_CROSS:quality=8.8>=7.5+momentum=6.0>=5.0 exempted
- 8K_FLAG:5.01
Reward-to-Risk
-0.87
Upside
-13.0%
Downside
15.0%
Sizing output
AVOID
Setup— — No clear chart pattern; technical signals are mixed
EdgeNo clear edge — No clear edge identified
SuitabilitySpeculative — Drawdown -41% (>40% off 52w high), Binary industry: Biotechnology
Investment implication
The F-path SELL output reflects an overall score of 5.3 below the 5.6 soft trigger — multiple weakening dimensions accumulated rather than a single hard-floor breach. The strongest dimension ( Quality at 8.8) was not enough to lift the adjusted overall above the threshold. Co-occurring failed gates ( ASYMMETRY:-0.9=NEGATIVE) reinforce the read. Current asymmetry R:R is -0.87 — supplementary context, not the trigger for this path.
The strongest dimensions are Quality at 8.8, Catalyst at 7.2, and Risk (lower is worse) at 6.9; the weakest are Technical at 1.0, Value at 2.9, and Peer rank at 4.5. The V9 engine flagged 1 failed gate with 2 warnings, producing an asymmetric reward-to-risk of -0.87 and an engine sizing output of AVOID.
What would invalidate the thesis
Falsifying conditions — when triggered, the corresponding pillar's thesis is invalidated.
- P1Elite Piotroski Commercial Launch
Trip ifNet margins fall below 15% in any reported quarterly period.
- P2Single Product Concentration
Trip ifVYKAT XR net revenue growth falls below 10% year-over-year for more than 2 consecutive quarters.
- P3Overbought At Rsi 93
Trip ifRSI remains above 80 for more than 60 consecutive calendar days, indicating sustained extreme overbought conditions.
- P4High Short Interest Squeeze Risk
Trip ifShort interest rises above 25%, increasing the overhang risk substantially.